Abstract

Severe cases of infections caused by Raoultella planticola are constantly being reported from all over the world with the increase in drug-resistance patterns. In this study, we retrospectively evaluated the clinical characteristics of R. planticola infections with patients' demographics and antimicrobial susceptibilities of the R. planticola isolates. R. planticola isolates were retrospectively evaluated. VITEK 2® automated system was used for identification and antimicrobial susceptibility testing. Verification of the low-discriminated isolates was analyzed with MALDI-TOF method using VITEK MS® system. Gene-Xpert® system was used for detection of bla IMP-1-, bla KPC-, bla NDM-1-, bla OXA-48- and bla VIM-type carbapenemases. The data of the patients with R. planticola infection were collected from hospital records. During the 4-year period, 42 episodes of R. planticola infections were detected. MALDI-TOF was used for 11 of the low-discriminated isolates, and 1 of which identified as R. terrigena was excluded. Carbapenems and aminoglycosides were the most effective antimicrobial agents. Extended spectrum beta-lactamases were detected in seven of the isolates. Three carbapenem-resistant isolates were detected as bla OXA-48-type carbapenemase carrier. Nosocomial R. planticola infections constituted 80.9% (n=34) of the infections. Most common infections related with R. planticola were blood stream infections (n=24) (p<0.005). The presence of indwelling catheter and intensive care unit stay were the most common detected risk factors (p<0.005). Diabetes mellitus and chronic renal insufficiency commonly accompanied the infections (p>0.005). Challenging infections caused by Raoultella spp., like those of multidrug resistant Klebsiella spp., will probably become a concern for clinicians as well as microbiologists . In literature, there were few cases, but we believe that the incidence of Raoultella spp. infections, which may result from misidentification, are more common than expected , and it is not unlikely that there will be a gradual increase and spread in multidrug-resistant isolates.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.